Abbott Laboratories (ABT) saw downtrend of -0.90% in the recent trading with $131.38 being its most recent. The current price level -6.97% lower than the highest price of $141.23 marked by the stock while trading over the past 52-weeks, whereas it is 18.51% higher than the lowest price of $110.86 the company dropped to over past 52-weeks. The latest news story on ABT appeared in (Yahoo Finance) under the title “Earnings live: JPMorgan, Citi, and other Wall Street banks set to lead off Q3 earnings season” on.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 13 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.88 for the stock.
Abbott Laboratories Earnings – What Happened With ABT
Coming around sales and income figures on ABT Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Abbott Laboratories (ABT) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 0.76% for net revenue.
ABT – Abbott Laboratories Stock Earnings Estimates
The perspective of Abbott Laboratories (NYSE:ABT)’s current quarter earnings identifies that analysts are in consensus over the estimate of 1.2 for stock’s EPS in the current quarter. Abbott Laboratories (ABT) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 0.76% for net revenue. Company’s EPS for the last quarter was 1.21.
Abbott Laboratories – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 1.74 billion. ABT does have institutional investors; and they hold 80.06% of the stock.
As on 2024-06-30, VANGUARD GROUP INC was the top most holder in Abbott Laboratories (NYSE:ABT) with an ownership of 166.35 million shares of the company or 9.5932 of the stake worth $17.29 billion. The filing also reveals BLACKROCK INC. as the second largest holder in the company with a control over 7.5619 of the outstanding shares. Its stake is worth $13.63 billion for having 131.13 million shares in hand.
STATE STREET CORP also came holding a key position in the company during the recent quarter and it now holds 4.2903 of the outstanding shares. With this there are now 3913.0 institutions which have possession in ABT’s shares.
Key Metrics for ABT
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Abbott Laboratories has a debt to equity ratio of 0.27.
